Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner

Abstract

Mice deficient for the mismatch repair (MMR) gene Msh2 show accelerated tumourigenesis and a reduced apoptotic response to DNA damage of methylation type. Here we examine the effect of mutation for Msh2 on in vivo mutation frequencies in the intestine as determined by loss of function at the Dolichos biflorus (Dlb-1) locus. Spontaneous mutation frequencies were scored in cohorts of ageing mice either wild type or mutant for Msh2. In mice less than 1 year old, mutation frequencies were only elevated in Msh2 null mice. However, beyond this age heterozygous Msh2 mice showed significantly higher mutation frequencies than controls. These findings implicate a gene dose dependent requirement for Msh2 in mutation suppression and prompted an analysis of young Msh2 mutants following exposure to DNA damage. Following exposure to N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), Msh2 deficient mice show a reduced apoptotic response and an increase in mutation frequency. Heterozygotes did not differ from controls. Following exposure to cisplatin, no significant elevation was seen in mutation frequencies, even within homozygotes. This is particularly surprising given the association between cisplatin resistance and MMR deficiency. These findings therefore demonstrate a complex reliance upon functional Msh2 in mutation surveillance. We have identified three separate scenarios. First, where retention of both Msh2 alleles over an extended period of time appears critical to the suppression of spontaneous mutation; second, 3 weeks following exposure to MNNG, where only complete loss of Msh2 results in elevated mutation; and finally following cisplatin exposure, where induced levels of mutation are independent of Msh2 status.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Andrew SE, McKinnon M, Cheng BS, Francis A, Penney J, Reitmair AH, Mak TW, Jirik FR . 1998 Proc. Natl. Acad. Sci. 95: 1126–1130

  • Branch P, Masson M, Aquilina G, Bignami M, Karran P . 2000 Oncogene 19: 3138–3145

  • Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA . 1997 Oncogene 15: 45–52

  • Buermeyer AB, Deschenes SM, Baker SM, Liskay RM . 1999 Ann. Rev. Genet. 33: 533–564

  • DeWeese TL, Shipman JM, Larrier NA, Buckley NM, Kidd LR, Groopman JD, Cutler RG, te Tiele H, Nelson WG . 1998 Proc. Natl. Acad. Sci. 95: 11915–11920

  • De Wind N, Dekker M, Berns A, Radman M, Riele HT . 1995 Cell 82: 321–330

  • De Wind N, Dekker M, vanRossum A, vanderValk M, Riele HT . 1998 Mouse models for hereditary nonpolyposis colorectal cancer Cancer Res. 58: 248–255

  • Drotschmann K, Clark AB, Tran HT, Resnick MA, Gordenin DA, Kunkel TA . 1999 Proc. Natl. Acad. Sci. USA 96: 2970–2975

  • Drotschmann K, Shcherbakova PV, Kunkel TA . 2000 Toxicol. Lett. 112: 239–244

  • Fink D, Aebi S, Howell SB . 1998 Clin. Cancer Res. 4: 1–6

  • Hickman MJ, Samson LD . 1999 Proc. Natl. Acad. Sci. USA 96: 10764–10769

  • Kawate H, Itoh R, Sakumi K, Nakabeppu Y, Tsuzuki T, Ide F, Ishikawa T, Noda T, Nawata H, Sekiguchi M . 2000 Carcinogenesis 21: 301–305

  • Kinzler KW, Vogelstein B . 1996 Cell 87: 159–170

  • Nicolades NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM et al . 1994 Nature (Lond.) 371: 75–79

  • Prolla TA, Baker SM, Harris AC, Tsao EL, Yao X, Bronner CE, Zheng BH, Gordon M, Reneker J, Arnheim N, Shibata D, Bradley A, Liskay RM . 1998 Nature Genet. 18: 276–279

  • Reitmair AH, Redston M, Cai JC, Chuang TCY, Bjerknes M, Cheng H, Hay K, Gallinger S, Bapat B, Mak TW . 1996 Cancer Res. 56: 3842–3849

  • Reitmair AH, Risley R, Bristow RG, Wilson T, Ganesh A, Jang A, Peacock J, Benchimol S, Hill RP, Mak TW, Fishel R, Meuth M . 1997 Cancer Res. 57: 3765–3771

  • Sansom OJ, Clarke AR . 2000 Mutation Res. 452: 149–162

  • Shcherbakova PV, Kunkel TA . 1999 Mol. Cell. Biol. 19: 3177–3183

  • Shoemaker AR, Moser AR, Dove WF . 1995 Cancer Res. 55: 4479–4485

  • Strathdee G, Sansom OJ, Sim A, Clarke AR, Brown R . 2001 Oncogene in press

  • Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, te Riele H, Arends MJ, Wyllie AH, Margison GP, Clarke AR . 1999 Proc. Natl. Acad. Sci. USA 96: 3911–3914

  • Wheeler JMD, Mortensen NJMcC, Bodmer WF . 2000 Gut 47: 148–153

  • Winton DJ, Blount M, Ponder BA . 1988 Nature (Lond.) 333: 463–466

Download references

Acknowledgements

This work was supported by the Royal Society and the Cancer Research Campaign.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sansom, O., Toft, N., Winton, D. et al. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner. Oncogene 20, 3580–3584 (2001). https://doi.org/10.1038/sj.onc.1204449

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1204449

Keywords

This article is cited by

Search

Quick links